[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institute of Gastroenterology and Hepatology, Vietnam\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":121},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,75,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100602592","evaluating-medication-adherence-of-patients-with-gastroesophageal-reflux-disease-with-support-of-the-smartphone-application-gerdcare-100602592",false,"NCT07125521","Evaluating Medication Adherence of Patients With Gastroesophageal Reflux Disease With Support of the Smartphone Application GERDCare","AppGERD","Inclusion Criteria:\n\n* ≥18 years old\n* Presents with typical GERD symptoms (regurgitation, heartburn)\n* Owns a smartphone and capable of using smartphone applications.\n\nExclusion Criteria:\n\n* Acute GI conditions (upper GI bleeding, acute peptic ulcer…)\n* GI malignancy (esophageal cancer, gastric cancer…)\n* Severe chronic comorbidities (heart failure, liver failure, chronic kidney disease…)\n* Pregnancy, alcohol abuse, mental health conditions impacting medication adherence or app usage","ALL","18 Years",{"count":19,"type":20},380,"ESTIMATED","INTERVENTIONAL",[23],"NA","Adherence to GERD treatment, including medication, diet, and lifestyle, is essential for symptom control and complication prevention, yet adherence rates remain low due to various demographic and clinical factors. Digital therapeutics, particularly mobile health applications, have shown promising potential in supporting chronic disease management and improving patient outcomes.\n\nThe GERDCare mobile application was developed with direct input from gastrointestinal experts. It is designed to enhance treatment adherence and patient engagement by offering features such as educational resources, symptom tracking, medication reminders, and direct communication between patients and physicians.\n\nThe investigators are conducting a single-center, open-label, randomized controlled trial to evaluate the effectiveness of using GERDCare in improving patient adherence. Patients are followed up after four weeks of GERD treatment.",[26],"GERD (Gastroesophageal Reflux Disease)",[28,29,30,31],"GERD","mobile apps","mobile applications","medication adherence","RECRUITING","2026-06-16",{"date":35,"type":36},"2026-06-17","ACTUAL",{"date":38,"type":36},"2025-08-18",{"date":40,"type":20},"2026-08-31",{"name":42,"class":43},"Institute of Gastroenterology and Hepatology, Vietnam","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100641679","effects-of-the-multispecies-probiotic-ecologic-barrier-in-ibs-patients-with-upper-gi-symptoms-and-anxiety-depression-or-stress-100641679","NCT07656623","Effects of the Multispecies Probiotic Ecologic Barrier in IBS Patients With Upper GI Symptoms and Anxiety, Depression, or Stress","The Effects of the Multispecies Probiotic Mixture Ecologic Barrier for Patients With Irritable Bowel Syndrome With Upper Gastrointestinal Symptoms and Having Anxiety, Depression, and Stress Symptoms","Inclusion Criteria:\n\n* Indication for upper endoscopy and colonoscopy;\n* Diagnosed with IBS-D according to Rome IV criteria;\n* Presence of at least one upper gastrointestinal symptom, including: retrosternal burning, reflux, epigastric pain, epigastric burning, postprandial discomfort, early satiety, abdominal bloating, belching, sour regurgitation, nausea\u002Fvomiting;\n* Manifestations of anxiety, depression, or stress, with at least one of the three DASS-21 subscale scores exceeding the normal threshold (depression score \\>9 and\u002For anxiety score \\>7 and\u002For stress score \\>14).\n\nExclusion Criteria:\n\n* Positive for Helicobacter pylori by rapid urease test during endoscopy or by 13C-urea breath test;\n* Currently using anxiolytic or antidepressant medication;\n* Currently or previously used antibiotics within the past month;\n* Currently or previously used symptomatic treatment, probiotics, or proton pump inhibitors (PPI) within the past two weeks;\n* History of gastrointestinal surgery;\n* Endoscopic findings of organic lesions: ulcer, acute inflammation, colonic polyp \\>5 mm, or colonic polyp \\\u003C5 mm with suspected neoplasia;\n* Pregnant or breastfeeding women.",{"count":53,"type":20},60,[23],"The aim of this clinical trial is to find out whether Ecologic Barrier is effective in supporting the treatment of irritable bowel syndrome (IBS) in adults. The main questions that this trial aims to answer are:\n\n* Does Ecologic Barrier help improve IBS severity when added to standard IBS treatment?\n* Does Ecologic Barrier help improve symptoms of anxiety, depression, and stress in patients with IBS?\n* Does Ecologic Barrier help improve upper gastrointestinal symptoms when added to standard IBS treatment?\n* What adverse events may occur when using Ecologic Barrier? The researchers will compare a group receiving standard symptom-based treatment with another group receiving standard treatment plus Ecologic Barrier.\n\nParticipants will:\n\n* Receive IBS treatment for 2 months, with Ecologic Barrier added during either the first month or the second month, depending on random assignment.\n* Attend a follow-up visit after 1 month of treatment.\n* Take part in interviews about IBS severity, symptom improvement, adverse events, and symptoms of depression and anxiety at baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks.",[57],"Irritable Bowel Syndrome With Diarrhea",[59,60,61,62,63,64,65,66],"Irritable bowel syndrome","IBS-D","Probiotics","DASS-21","Upper gastrointestinal symptoms","Stress","Depression","Anxiety","2026-06-15",{"date":69,"type":36},"2026-06-18",{"date":71,"type":36},"2024-06-01",{"date":73,"type":20},"2026-06-30",{"name":42,"class":43},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100634511","assessment-of-treatment-adherence-and-associated-factors-in-chronic-hepb-patients-supported-by-hbvcare-100634511","NCT07540637","Assessment of Treatment Adherence and Associated Factors in Chronic HepB Patients Supported by HBVCare","Assessment of Treatment Adherence and Associated Factors in Chronic Hepatitis B Patients With Supported Management by the HBVCare Application.","HBVCare","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Diagnosis of Chronic Hepatitis B (CHB): HBsAg (+) and\u002For HBV DNA positive for ≥ 6 months; Or HBsAg positive and anti-HBc IgM negative.\n* Smartphone ownership (iOS or Android) with an active internet connection and the ability to install the HBVCare application.\n* Sufficient literacy to read and understand Vietnamese and respond to study questions.\n* Provision of informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Mental health disorders, cognitive impairment, or difficulties in communication and mobile application usage.\n* Severe comorbid chronic conditions, such as heart failure, kidney failure, or respiratory failure.\n* Presence of severe complications, including gastrointestinal bleeding, liver cancer, hepatic encephalopathy, or acute liver failure.",{"count":84,"type":20},70,[23],"Adherence to chronic Hepatitis B (HBV) treatment and regular follow-up visits is essential for preventing dangerous complications, yet adherence rates in Vietnam remain low due to barriers in patient awareness and geographic conditions. Digital health solutions, particularly mobile applications, have shown potential as tools for supporting patients in proactive disease management. The HBVCare mobile application was developed to provide features such as medication reminders, storage of lab results, and health education to improve treatment adherence and clinical outcomes. The investigators are conducting a multicenter, randomized controlled trial at Hoang Long Clinic and Hanoi Medical University Hospital to evaluate the effectiveness of HBVCare. Patients are randomized into either a control group receiving standard care and an intervention group using the HBVCare app, with patient adherence and related factors assessed after three months of treatment.",[88],"Chronic Hepatitis B",[88,90,91,31],"Digital health","mobile application","2026-05-13",{"date":94,"type":36},"2026-05-15",{"date":96,"type":36},"2026-04-15",{"date":98,"type":20},"2026-12-31",{"name":42,"class":43},2,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":44},"100602727","evaluating-medication-adherence-of-patients-with-gastroesophageal-reflux-disease-with-support-of-smartphone-application-gerdcare-100602727","NCT07127276","Evaluating Medication Adherence of Patients With Gastroesophageal Reflux Disease With Support of Smartphone Application GERDCare",{"count":19,"type":20},[23],"Adherence to GERD treatment, including medication, diet, and lifestyle, is essential for symptom control and complication prevention, yet adherence rates remain low due to various demographic and clinical factors. Digital therapeutics, particularly mobile health applications, have shown promising potential in supporting chronic disease management and improving patient outcomes.\n\nThe GERDCare mobile application was developed with direct input from gastrointestinal experts. It is designed to enhance treatment adherence and patient engagement by offering features such as educational resources, symptom tracking, medication reminders, and direct communication between patients and physicians.\n\nWe are conducting a single-center, open-label, randomized controlled trial to evaluate the effectiveness of using GERDCare in improving patient adherence. Patients are followed up after four weeks of GERD treatment.",[26],[28,111,29,30,31],"Gastroesophageal reflux disease","NOT_YET_RECRUITING","2025-08-10",{"date":115,"type":36},"2025-08-17",{"date":117,"type":20},"2025-08-15",{"date":119,"type":20},"2025-10-31",{"name":42,"class":43},""]